Remission Induction with Tacrolimus for Intractable Ulcerative Colitis: A Retrospective Study of Remission Rates, Maintenance at 52 Weeks, Drug-Specific Maintenance, and Safety

• DOI: 10.20944/preprints202307.0913.v1
• Publication Date: 2023-07-14T02:16:47Z
• Authors: Ayumi Ito; Shun Murasugi; Teppei Omori; Shinichi Nakamura; Katutoshi Tokushige
• Keywords: Discontinuation; Maintenance therapy; Prednisolone; Maintenance dose

Background and Aim: Tacrolimus is highly effective in intractable ulcerative colitis, but maintenance may be problematic. This study examined 52-week adverse events.
 Methods: retrospective of patients who used tacrolimus from April 2009 to December 2021 (N = 136) remission induction rates background factors the (n 108) non-remission groups 28); maintenance; drug-specific (azathioprine [n 58] vs 12] biological product [Bio, n 8]); Results: The mean observation period was 1230175 days. Remission occurred 72.7%. Significant differences were observed sex endoscopic score (before treatment 2 weeks after trough levels). Maintenance rate at 52 61.6%; significant sex, hospitalization duration, prednisolone during (P < 0.05). Drug-specific 67% with azathioprine, 54% tacrolimus, 37% Bio. No tacrolimus-related serious events that led discontinuation.
 Discussion: more common women improved scores levels therapy. a long high total steroid dose. Results suggest adequate use inflammation improve subsequent maintenance.
 Conclusions: In can induce even cannot azathioprine for maintenance. maintained or